The reigning theory underlying cardiovascular disease, the lipid hypothesis, suffered a defeat this week at the hands of the inflammatory hypothesis when canakinumab, a human monoclonal antibody that targets interleukin-1β [1] was
Noteworthy findings and developments that don't fit neatly into one field — physics, ecology, climate science, astronomy, and other discoveries worth knowing about.
